Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 30Pancreatic Neoplasms 10Squamous Cell Carcinoma of Head and Neck 8Rectal Neoplasms 7Lung Neoplasms 7Gliosarcoma 7Glioblastoma 7Colonic Neoplasms 7Carcinoma, Hepatocellular 7Brain Neoplasms 7Esophageal Neoplasms 5Carcinoma, Renal Cell 5Astrocytoma 5Adenocarcinoma of Lung 5Salivary Gland Neoplasms 4Gallbladder Neoplasms 4Carcinoma, Ovarian Epithelial 4Bile Duct Neoplasms 4Adenocarcinoma, Bronchiolo-Alveolar 4Oligodendroglioma 3Esthesioneuroblastoma, Olfactory 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Tongue Neoplasms 2Stomach Neoplasms 2Pancreatic Intraductal Neoplasms 2Mesothelioma, Malignant 2Medulloblastoma 2Hereditary leiomyomatosis and renal cell cancer 2

Interventions

dehydroftorafur 2Leucovorin 2Fluorouracil 2trametinib 1binimetinib 1Specimen Handling 1Sorafenib 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Erlotinib Hydrochloride 1Capecitabine 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Klatskin Tumor × Erlotinib Hydrochloride × Clear all
NCT01093222 2015-06-30

Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

National Cancer Institute (NCI)

Phase 2 Completed
40 enrolled 16 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡